secwatch / observer
8-K filed May 4, 2026, 7:59 PM ET ticker CNSP CIK 0001729427
other material confidence high sentiment neutral materiality 0.60

CNS Pharma raises ~$22.5M in private placement at $2.30/sh; board change

CNS Pharmaceuticals, Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001683168-26-003432
form_type
8-K
ticker
CNSP
cik
0001729427
company_name
CNS Pharmaceuticals, Inc.
filed_at
2026-05-04T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.821167+00:00
generated_at
2026-05-14T23:57:08.200890+00:00
sec_items
["1.01", "3.02", "5.02", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001683168-26-003432
json_url
https://secwatch.observer/filing/0001683168-26-003432.json
markdown_url
https://secwatch.observer/filing/0001683168-26-003432.md
text_url
https://secwatch.observer/filing/0001683168-26-003432.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1729427/000168316826003432/0001683168-26-003432-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1729427/000168316826003432/cns_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jerzy (George) Gumulka

Director
CNSP · CNS Pharmaceuticals, Inc.
Effective
2026-05-04
Successor
Michal Fisher
Filed
May 4, 2026, 7:59 PM ET
On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Appointed

Michal Fisher

Independent Director
CNSP · CNS Pharmaceuticals, Inc.
Effective
2026-05-04
Filed
May 4, 2026, 7:59 PM ET
On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company’s Board.

Source-grounded claims

66a98cac9b

Jerzy (George) Gumulka resigned as Director at CNS Pharmaceuticals, Inc..

On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

d5c88aece0

Michal Fisher was appointed as Independent Director at CNS Pharmaceuticals, Inc..

On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company’s Board.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

44ba1e6f9e75e11e792f1094889724a6887c1c71

CNS Pharmaceuticals, Inc. entered into Registration Rights Agreement (effective 2026-05-04).

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

88803a4b4aeb3ffc5e5cafcda0550007f26d090d

CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with institutional investors valued at $22.5 million (effective 2026-05-04).

On May 4, 2026, CNS Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Investors purchased in a private placement: (i) 650,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”) at a purchase price of $2.30 per share; and (ii) pre-funded warrants to purchase 9,143,479 shares of the Common Stock (the “Pre-Funded Warrants”) at a purchase price of $2.299 per Pre-Funded Warrant (the “Offering”).

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

9263dc418697aa4ed6c71136c6943dde4928a0b2

CNS Pharmaceuticals, Inc. entered into Placement Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the gross proceeds (effective 2026-05-04).

On May 4, 2026, the Company entered into a placement agency agreement (the “Placement Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”), pursuant to which the Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the transaction.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

CITR

CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights

CitroTech Inc. June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock

Filing page SEC filing

CRMT

America's Car-Mart forms special committee for strategic alternatives; appoints new independent director

AMERICAS CARMART INC May 29, 2026, 5:30 PM ET other_material Items 1.01, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Comparable filing

On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.

Filing page SEC filing

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).

Filing page SEC filing

GIPR

Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit

GENERATION INCOME PROPERTIES, INC. June 1, 2026, 5:27 PM ET other_material Items 1.01, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent

Filing page SEC filing

LOKV

Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54

Live Oak Acquisition Corp. V June 1, 2026, 5:00 PM ET other_material Items 1.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (" Live Oak "), and HB Strategies LLC (" Seller " or " FPA Investor ") entered into an agreement (the " Forward Purchase Agreement ") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the " Forward Purchase Transaction ") in connection with Live Oak’s proposed initial business combination (the " Business Combination ") with Teamshares Inc., a Delaware corporation (" Teamshares " and the surviving public company following consummation of the Business Combination, the " Combined Company "), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the " Merger Agreement ").

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).

Filing page SEC filing

BBDC

Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments

Barings BDC, Inc. June 1, 2026, 4:15 PM ET other_material Items 1.01, 1.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).

Filing page SEC filing

LTRX

Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M

LANTRONIX INC June 1, 2026, 4:15 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date

Comparable filing

On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock

Filing page SEC filing

Source: SEC EDGAR
accession 0001683168-26-003432

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.